Peptide Research Week in Review: 20-27 July 2026
TL;DR: This week: retatrutide's TRIUMPH-2/3 hit their endpoints (23 Jul) and FDA's PCAC backed 6 of 7 compounding peptides (23-24 Jul).
What Happened in Peptide Research This Week (20-27 July 2026)?
Two stories accounted for almost all of this week's substantive peptide-adjacent news. On 23 July, Eli Lilly announced topline Phase 3 results for retatrutide's two remaining TRIUMPH trials, TRIUMPH-2 and TRIUMPH-3.[1] We covered the full data set in detail the following day — see our TRIUMPH-2 & TRIUMPH-3 results guide for the complete breakdown, including dose-by-dose figures and the cardiovascular sub-analysis.
Almost simultaneously, on 23-24 July, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met to vote on whether seven peptides — including BPC-157 and TB-500 — should be recommended for the Section 503A Bulk Drug Substances list.[3] Our PCAC vote outcome guide has the full vote-by-vote tally. Both stories are distinct — one is a licensed pharmaceutical company's clinical trial programme, the other a US compounding-pharmacy policy debate — but read together they say something useful about how far headline news sits from an enforceable regulatory outcome.
What Did Retatrutide's TRIUMPH-2 and TRIUMPH-3 Trials Report?
TRIUMPH-2 (n=1,152, type 2 diabetes + obesity/overweight): up to 20.8% mean weight loss at 80 weeks on the 12mg dose versus 4% on placebo, with A1C reductions of up to 1.6 percentage points.
TRIUMPH-3 (n=1,949, obesity/overweight + established cardiovascular disease): up to 22.6% mean weight loss at 80 weeks on 12mg versus 3.2% on placebo. TRIUMPH-3's pre-specified cardiovascular (MACE) analysis was statistically underpowered and did not read as either reassuring or concerning — both hazard-ratio confidence intervals crossed 1.
Source: Eli Lilly, 23 July 2026 · full figures in our TRIUMPH-2 & TRIUMPH-3 results guide
Four of five TRIUMPH-branded trials, plus the separately branded TRANSCEND-T2D-1 diabetes trial, have now all read out. Only the dedicated, event-driven cardiovascular and kidney outcomes trial (NCT06383390, roughly 10,000 participants) remains, not expected before 2027. Lilly's release states the company now plans a Biologics License Application (BLA) in Q1 2027 — later than the Q4 2026 target reported in earlier trade press. See our FDA approval timeline guide for the fuller picture.
What Did the FDA's PCAC Vote Decide on 23-24 July?
Over two days at FDA's White Oak campus, the committee voted on seven peptides removed from Section 503A Category 2 in April 2026. Six received a favourable recommendation: BPC-157, KPV and TB-500 together (8-6, one abstention), MOTS-c (7-5, two abstentions), Semax (8-5) and Epitalon (7-4).[3] DSIP (listed under its INN, emideltide) was the sole rejection, by a narrow 6-7 margin. The outcome ran directly counter to FDA staff's own pre-meeting scientific review, which had recommended against adding any of the seven to the bulks list, citing thin human safety and efficacy data.[3]
As our vote-outcome guide details, this is a recommendation, not a rule: the PCAC's vote is advisory only, and the FDA must still independently review it and complete a formal notice-and-comment rulemaking process before any of the six recommended peptides could actually be added to the 503A list — a process trade-press and legal-industry sources put at roughly 6-18 months, with no fixed start date yet announced.[4]
How Do This Week's Two Biggest Stories Connect?
Both stories make the same point from opposite directions: a headline result is one step in a longer regulatory chain, not the final one. Retatrutide has now cleared five separate Phase 3 or Phase 3-equivalent readouts, every one positive on its primary endpoint — yet Lilly's BLA filing still isn't due until Q1 2027. Five positive readouts do not compress the licensed-medicine pathway.
The PCAC vote runs the same logic in reverse. A committee recommendation feels like a decision because it is reported as a vote count with winners and losers. It is not one: the FDA can still decline to act on it, and even a full rulemaking process — the step that would actually change any compounding pharmacy's legal position — has neither started nor been scheduled as of this week.
For researchers tracking either compound class, the practical read is the same: treat topline announcements and advisory votes as directional signals worth logging, not as changes in legal or regulatory status until the formal step (a BLA decision; a completed rulemaking) actually lands.
What Happens Next?
| Track | Next milestone | Expected timing |
|---|---|---|
| Retatrutide (Lilly) | BLA submission to FDA | Q1 2027 |
| Retatrutide CVOT (NCT06383390) | Event-driven read-out | Not before 2027 |
| PCAC batch 1 (6 recommended peptides) | FDA rulemaking decision | No date announced; ~6-18 months typical |
| PCAC batch 2 | Second hearing: GHK-Cu, Melanotan II, LL-37, DiHexa, PEG-MGF | Before end February 2027 |
The second PCAC batch is worth flagging on its own: it covers five further peptides removed from Category 2 alongside the first seven in April 2026 but held back for a separate session, including two compounds in Velox's own catalogue, GHK-Cu and Melanotan II.[5] We break down that hearing's scope and timeline in our GHK-Cu & Melanotan-II PCAC date guide.
What Should UK Researchers Take From This Week?
Neither story changes anything about the regulatory status of research peptides in the UK. Retatrutide remains an unlicensed, investigational compound with no MHRA marketing authorisation. BPC-157, TB-500, KPV, MOTS-c, Semax and DSIP remain unlicensed research reagents regardless of how the US 503A rulemaking eventually resolves — the Section 503A Bulk Drug Substances List is a US compounding-pharmacy mechanism with no bearing on UK supply, which sits under the Human Medicines Regulations 2012 and MHRA guidance. See our guide on whether research peptides are legal in the UK for the fuller picture.
These compounds are supplied as research reagents only. None are medicines and none have been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- Eli Lilly and Company. “Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C.” 23 July 2026. investor.lilly.com
- Velox Peptides. “Retatrutide TRIUMPH-2 and TRIUMPH-3 Report: Diabetes and Cardiovascular Phase 3 Results.” 24 July 2026. veloxpeps.com
- NPR. “FDA advisers vote to ease peptide restrictions, despite agency concerns.” 23 July 2026. npr.org
- Restore Health Consulting. “FDA Peptides Meeting July 2026: What Happens After the PCAC Vote.” July 2026. restorehealthconsulting.com
- Velox Peptides. “GHK-Cu & Melanotan-II PCAC Date: Feb 2027.” 11 July 2026. veloxpeps.com
Frequently Asked Questions
What are the two biggest peptide research stories this week (20-27 July 2026)?
Eli Lilly reported topline Phase 3 results for retatrutide's TRIUMPH-2 and TRIUMPH-3 trials on 23 July 2026, and the FDA's Pharmacy Compounding Advisory Committee voted on 23-24 July 2026 to recommend six of seven peptides, including BPC-157 and TB-500, for the Section 503A bulk drug substances list.
Did retatrutide's TRIUMPH-2 and TRIUMPH-3 trials succeed?
Both trials met their weight-loss primary endpoints. TRIUMPH-2, in adults with type 2 diabetes and obesity, reported up to 20.8% mean weight loss at 80 weeks on the 12mg dose. TRIUMPH-3, in adults with obesity and established cardiovascular disease, reported up to 22.6%. TRIUMPH-3's pre-specified cardiovascular (MACE) analysis was underpowered and statistically inconclusive.
Which peptides did the FDA's PCAC vote recommend for compounding?
The committee recommended BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. DSIP (emideltide) was the only one of the seven peptides reviewed that the committee voted against, by a narrow 6-7 margin. The vote is advisory only and does not itself change any peptide's legal status.
Does the PCAC vote or the TRIUMPH data change UK research-reagent supply?
No. Both stories are US-specific: the PCAC process governs US compounding pharmacies and retatrutide's BLA process governs licensed pharmaceutical approval in the US. Neither affects the UK regulatory status of research peptides, which is governed by the Human Medicines Regulations 2012 and MHRA guidance. Velox Peptides supplies all listed compounds as HPLC-verified in vitro research reagents only.
What's the next milestone to watch for in peptide regulation?
Two dates: Eli Lilly's planned Q1 2027 BLA submission for retatrutide, and a second FDA PCAC meeting expected before the end of February 2027 covering five more peptides removed from Category 2 alongside the first batch — GHK-Cu, Melanotan II, LL-37, DiHexa and PEG-MGF.